Inhaled activated protein C: a novel therapy for acute lung injury?

doi:10.1186/cc7869

Critical Care
Volume 13
Issue 3

Viewing options:

Abstract
Full text
PDF (43KB)

Associated material:

Related literature:

Articles citing this article
on Google Scholar
on ISI Web of Science
on PubMed Central
Other articles by authors
on Google Scholar

Liu KD
Looney MR
Matthay MA

on PubMed

Liu KD
Looney MR
Matthay MA
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Nominate for award

Post to:

Commentary

Inhaled activated protein C: a novel therapy for acute lung injury?

Kathleen D Liu¹ , Mark R Looney² and Michael A Matthay²

¹Divisions of Nephrology and Critical Care Medicine, Departments of Medicine and Anesthesia, University of California, San Francisco, San Francisco, CA 94143-0624, USA

²Cardiovascular Research Institute and the Division of Pulmonary and Critical Care Medicine, Departments of Medicine and Anesthesia, University of California, San Francisco, San Francisco, CA 94143-0624, USA

author email corresponding author email

Critical Care 2009, 13:150doi:10.1186/cc7869


Published:	21 May 2009

See related research by Waerhaug et al., http://ccforum.com/content/13/2/R51

Abstract

Acute lung injury (ALI) is characterized by the presence of dysregulated coagulation and inflammation. Therefore, Waerhaug and colleagues hypothesized that administration of activated protein C (APC) via the inhaled route would be a novel and effective treatment for ALI. They demonstrated that inhaled APC improved oxygenation and lung aeration in a sheep model of lipopolysaccharide-induced ALI, but did not alter lung water or hemodynamics. Future studies are needed to determine plasma and airspace APC levels when administered by the inhaled route, and to determine if inhaled APC has a similar effect in other models of ALI.